AR091567A1 - Preparacion liquida, metodo, kit de inyeccion - Google Patents
Preparacion liquida, metodo, kit de inyeccionInfo
- Publication number
- AR091567A1 AR091567A1 ARP130102255A AR091567A1 AR 091567 A1 AR091567 A1 AR 091567A1 AR P130102255 A ARP130102255 A AR P130102255A AR 091567 A1 AR091567 A1 AR 091567A1
- Authority
- AR
- Argentina
- Prior art keywords
- liquid preparation
- methylmethanamine
- pyrrol
- pyridin
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/04—Chlorides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/10—Bromides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/20—Halides
- C01F11/24—Chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Geology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se proporcionan una preparación líquida en donde el principio farmacéuticamente activo es estabilizado, y un método estabilizante para ello. Una preparación líquida que comprende un principio farmacéuticamente activo con un grupo amino primario o secundario (en donde el grupo amino no constituye una parte de la estructura de amida), un ácido orgánico y una sal, que está sustancialmente libre de un producto de reacción del principio farmacéuticamente activo y el ácido orgánico. Reivindicación 5: La preparación líquida de acuerdo a la reivindicación 1, caracterizado porque el principio farmacéuticamente activo es un compuesto no peptídico. Reivindicación 8: La preparación líquida de acuerdo a la reivindicación 5, caracterizado porque el compuesto no peptídico es 1-{5-(2-fluorofenil)-1-[(6-metilpiridin-3-il)sulfonil]-1H-pirrol-3-il}-N-metilmetanamina, 1-[4-fluoro-5-fenil-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina, N-metil-1-[5-(4-metil-3-tienil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]metanamina, 1-[5-(2-fluorofenil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina, N-metil-1-[5-(2-metilfenil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]metanamina, 1-{4-fluoro-5-(2-fluoropiridin-3-il)-1-[(4-metilpiridin-2-il)sulfonil]-1H-pirrol-3-il}-N-metilmetanamina, o 1-[4-fluoro-5-(2-fluoropiridin-3-il)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina. Reivindicación 11: La preparación líquida de acuerdo a la reivindicación 1, caracterizado porque donde el ácido orgánico es una o más clases seleccionadas del grupo que consiste en ácido ascórbico, ácido benzoico, ácido sórbico, ácido fumárico y ácido maleico. Reivindicación 14: La preparación líquida de acuerdo a la reivindicación 1, caracterizado porque la sal es una o más clases seleccionadas del grupo que consiste en cloruro de sodio, cloruro de calcio, cloruro de magnesio, bromuro de sodio y bromuro de calcio. Reivindicación 22: Una preparación liofilizada obtenida mediante la liofilización de la preparación líquida de acuerdo a la reivindicación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012144750 | 2012-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091567A1 true AR091567A1 (es) | 2015-02-11 |
Family
ID=48795873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102255 AR091567A1 (es) | 2012-06-27 | 2013-06-26 | Preparacion liquida, metodo, kit de inyeccion |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20150165027A1 (es) |
| EP (1) | EP2866788B1 (es) |
| JP (1) | JP6216338B2 (es) |
| KR (1) | KR102206928B1 (es) |
| CN (3) | CN110917130A (es) |
| AR (1) | AR091567A1 (es) |
| AU (1) | AU2013281626A1 (es) |
| BR (1) | BR112014031282A2 (es) |
| CA (1) | CA2877619C (es) |
| HK (1) | HK1209338A1 (es) |
| IL (1) | IL236187A0 (es) |
| MX (1) | MX2014015269A (es) |
| NZ (1) | NZ703528A (es) |
| PH (1) | PH12014502863A1 (es) |
| RU (1) | RU2015102333A (es) |
| SG (1) | SG11201408511QA (es) |
| TW (1) | TWI623327B (es) |
| UY (1) | UY34880A (es) |
| WO (1) | WO2014003199A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105982867A (zh) * | 2015-02-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 一种h009冻干粉针及其制备方法 |
| CN104814964B (zh) * | 2015-04-16 | 2018-07-31 | 广东赛烽医药科技有限公司 | 一种抗胃幽门螺旋杆菌的药物组合物、制备方法及其应用 |
| CN106265535A (zh) * | 2015-06-23 | 2017-01-04 | 中美华世通生物医药科技（武汉）有限公司 | 富马酸沃诺拉赞冻干粉针制剂及其制备方法 |
| CN104926790B (zh) * | 2015-06-29 | 2017-07-07 | 江苏奥赛康药业股份有限公司 | 一种高纯度Vonoprazan Fumarate化合物及其中间体、杂质以及它们的制备方法 |
| CN106511344A (zh) * | 2015-09-14 | 2017-03-22 | 王虹 | 一种胃酸分泌抑制剂的新用途 |
| RU2657833C2 (ru) * | 2015-12-01 | 2018-06-15 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение |
| CN105640877A (zh) * | 2016-01-26 | 2016-06-08 | 北京阜康仁生物制药科技有限公司 | 一种含有沃诺拉赞的液体制剂 |
| CN107525877B (zh) * | 2016-06-20 | 2021-08-03 | 重庆医药工业研究院有限责任公司 | 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法 |
| EA030671B1 (ru) * | 2016-07-20 | 2018-09-28 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Препарат для лечения костных поражений, вызванных злокачественными новообразованиями |
| CN107536801B (zh) * | 2017-08-18 | 2019-08-06 | 常州兰陵制药有限公司 | 氯化钙溴化钠注射液的制备工艺 |
| CN108689991B (zh) * | 2018-06-11 | 2019-12-20 | 杭州中美华东制药有限公司 | 沃诺拉赞新晶型盐及其制备方法 |
| CN110917201A (zh) * | 2019-12-02 | 2020-03-27 | 吉林省博大伟业制药有限公司 | 聚普瑞锌在制备治疗萎缩性胃炎伴随胃粘膜上皮异型增生的药物中的应用 |
| CN113350271B (zh) * | 2020-03-04 | 2025-01-17 | 广东东阳光药业股份有限公司 | 一种质子泵抑制剂的组合物及其制备方法 |
| HUE070031T2 (hu) * | 2020-06-17 | 2025-05-28 | Ildong Pharmaceutical Co Ltd | Új savszekréciós inhibitor és alkalmazása |
| CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
| CN114904001A (zh) * | 2021-02-06 | 2022-08-16 | 南京柯菲平盛辉制药有限公司 | 一种含有醋酸沃诺拉赞的药物组合物及其制备方法 |
| JP2024545449A (ja) * | 2021-12-15 | 2024-12-06 | デウン ファーマシューティカル カンパニー リミテッド | フェックスプラザン注射剤組成物の用法用量 |
| CN116462659B (zh) * | 2022-01-19 | 2024-09-17 | 天地恒一制药股份有限公司 | 一种伏诺拉生盐、其晶型及其制备方法与应用 |
| CN116270443A (zh) * | 2022-10-27 | 2023-06-23 | 广州白云山天心制药股份有限公司 | 富马酸伏诺拉生注射液及其制备方法 |
| WO2025064381A1 (en) * | 2023-09-18 | 2025-03-27 | Phathom Pharmaceuticals Inc. | Method for preparing vonoprazan with reduced nitrosamine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19833119A1 (de) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
| CN1326524C (zh) * | 2000-04-24 | 2007-07-18 | 第一制药株式会社 | 稳定的液体制剂 |
| MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| CA2473412A1 (en) * | 2004-07-08 | 2006-01-08 | Laboratoires Omega Ltee | Liquid pharmaceutical injectable formulation of octreotide |
| EP1803709B1 (en) | 2004-09-30 | 2013-01-02 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| ATE504567T1 (de) * | 2005-08-30 | 2011-04-15 | Takeda Pharmaceutical | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl-substitutierte 1-h-pyrrolderivate als säuresekretionshemmer |
| US7994205B2 (en) | 2006-03-31 | 2011-08-09 | Takeda Pharmaceutical Company Limited | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| US8658183B2 (en) * | 2007-08-09 | 2014-02-25 | Taigen Biotechnology Company, Ltd. | Antimicrobial parenteral formulation |
| WO2009041705A2 (en) | 2007-09-28 | 2009-04-02 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compounds as proton pump inhibitors |
| EP2196459B1 (en) | 2007-09-28 | 2016-11-02 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compound |
| EA201170272A1 (ru) * | 2008-07-28 | 2011-10-31 | Такеда Фармасьютикал Компани Лимитед | Фармацевтическая композиция |
| ES2423289T3 (es) | 2008-08-27 | 2013-09-19 | Takeda Pharmaceutical Company Limited | Compuestos de pirrol |
| BRPI1009090A2 (pt) | 2009-03-26 | 2016-03-01 | Takeda Pharmaceutical | composto, pró-droga, medicamento, métodos, e, uso do composto |
-
2013
- 2013-06-26 CN CN201911035338.XA patent/CN110917130A/zh active Pending
- 2013-06-26 CA CA2877619A patent/CA2877619C/en active Active
- 2013-06-26 JP JP2014561221A patent/JP6216338B2/ja active Active
- 2013-06-26 MX MX2014015269A patent/MX2014015269A/es unknown
- 2013-06-26 AR ARP130102255 patent/AR091567A1/es unknown
- 2013-06-26 WO PCT/JP2013/068192 patent/WO2014003199A1/en not_active Ceased
- 2013-06-26 NZ NZ703528A patent/NZ703528A/en not_active IP Right Cessation
- 2013-06-26 KR KR1020157002034A patent/KR102206928B1/ko active Active
- 2013-06-26 RU RU2015102333A patent/RU2015102333A/ru not_active Application Discontinuation
- 2013-06-26 BR BR112014031282A patent/BR112014031282A2/pt not_active IP Right Cessation
- 2013-06-26 HK HK15110093.8A patent/HK1209338A1/xx unknown
- 2013-06-26 EP EP13737879.0A patent/EP2866788B1/en active Active
- 2013-06-26 CN CN201380044649.7A patent/CN104582687A/zh active Pending
- 2013-06-26 UY UY0001034880A patent/UY34880A/es not_active Application Discontinuation
- 2013-06-26 SG SG11201408511QA patent/SG11201408511QA/en unknown
- 2013-06-26 TW TW102122662A patent/TWI623327B/zh active
- 2013-06-26 US US14/407,174 patent/US20150165027A1/en active Pending
- 2013-06-26 CN CN201910298076.XA patent/CN110200903B/zh active Active
- 2013-06-26 AU AU2013281626A patent/AU2013281626A1/en not_active Abandoned
-
2014
- 2014-12-11 IL IL236187A patent/IL236187A0/en unknown
- 2014-12-22 PH PH12014502863A patent/PH12014502863A1/en unknown
-
2022
- 2022-12-16 US US18/082,799 patent/US20230143246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201408511QA (en) | 2015-01-29 |
| PH12014502863A1 (en) | 2015-02-23 |
| WO2014003199A1 (en) | 2014-01-03 |
| CN104582687A (zh) | 2015-04-29 |
| CA2877619A1 (en) | 2014-01-03 |
| JP2015521986A (ja) | 2015-08-03 |
| KR102206928B1 (ko) | 2021-01-22 |
| CN110200903B (zh) | 2022-07-29 |
| AU2013281626A1 (en) | 2015-01-22 |
| US20230143246A1 (en) | 2023-05-11 |
| UY34880A (es) | 2014-01-31 |
| HK1209338A1 (en) | 2016-04-01 |
| RU2015102333A (ru) | 2016-08-20 |
| TWI623327B (zh) | 2018-05-11 |
| MX2014015269A (es) | 2015-02-20 |
| CN110200903A (zh) | 2019-09-06 |
| KR20150023883A (ko) | 2015-03-05 |
| CA2877619C (en) | 2020-09-22 |
| NZ703528A (en) | 2016-08-26 |
| BR112014031282A2 (pt) | 2017-06-27 |
| EP2866788B1 (en) | 2020-12-16 |
| US20150165027A1 (en) | 2015-06-18 |
| JP6216338B2 (ja) | 2017-10-18 |
| IL236187A0 (en) | 2015-01-29 |
| CN110917130A (zh) | 2020-03-27 |
| EP2866788A1 (en) | 2015-05-06 |
| TW201406399A (zh) | 2014-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091567A1 (es) | Preparacion liquida, metodo, kit de inyeccion | |
| ECSP19003047A (es) | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica | |
| PH12015501620A1 (en) | Pharmaceutical composition with improved bioavailability | |
| BRPI1016228A8 (pt) | formulações de eletrólito compatibilizadas | |
| MX2019013142A (es) | Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion. | |
| PE20091960A1 (es) | Compuestos de insulina lispro pegilada | |
| BR112016024509A2 (pt) | composições detergentes de dose unitária | |
| BR112015002153A2 (pt) | composto heterocíclico parcialmente saturado contendo nitrogênio | |
| MX2015006412A (es) | Antagonistas de cxcr7. | |
| CO6321127A2 (es) | Composición agroquímica que comprende una alquilamida de cadena larga n,n-dialquilo y mètodo para preparar y utilizar la misma | |
| EA200970981A1 (ru) | Пептидная смесь в качестве стабилизатора вина | |
| CR20120061A (es) | Tableta | |
| PE20142439A1 (es) | Formulacion en capsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dietiletilo | |
| MX2018007102A (es) | Pesticidas de azol biciclicos sustituidos con heterociclo. | |
| BR112018005844A2 (pt) | ?produto antitranspirante em aerossol, utilização de um produto antitranspirante e método para obter um benefício de antitranspirância? | |
| CO6150180A2 (es) | Sales de bencimidazolil-piridil-eteres y formulaciones de las mismas | |
| RU2014139857A (ru) | Полипептиды и их применение | |
| UY29652A1 (es) | Mezclas fungicidas a base de bifenilamidas de ácido pirazolcarboxílico 3-monosustituidas | |
| HK1213806A1 (zh) | 製造樹脂酊的方法 | |
| CA2896792C (en) | Stabilized cyazofamid composition | |
| AR071271A1 (es) | Ciclopropancarboxilato y composicion que lo contienen y metodo de control de plagas | |
| UA110882C2 (uk) | Фармацевтична композиція та спосіб її отримання | |
| EA201890963A1 (ru) | Соли палбоциклиба | |
| PA8852601A1 (es) | Antagonistas del receptor de angiotensina ii | |
| RU2015106366A (ru) | Препарат для лечения туберкулеза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |